HER-2-neu, CEA Peptides, GM-CSF, Montanide ISA-51 Vaccine
A vaccine comprised of HER-2-neu and carcinoembryonic antigen synthetic (CEA) peptides, combined with the adjuvants granulocyte-macrophage colony stimulating factor (GM-CSF), and Montanide ISA-51 with potential antineoplastic activity. HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine may stimulate a cytotoxic T-cell response against HER-2-neu- and CEA-expressing tumor cells. The GM-CSF adjuvant stimulates the proliferation of monocytes and monocyte differentiation into macrophages and dendritic cells, immunohematopoietic elements with important antitumoral functions. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. [ ]
Term info
HER-2-neu, CEA Peptides, GM-CSF, Montanide ISA-51 Vaccine
- HER-2-neu, CEA Peptides, GM-CSF, Montanide ISA-51 Vaccine
Obsolete_Concept
HER-2-neu_CEA_Peptides_GM-CSF_Montanide_ISA-51_Vaccine
442901
442901
HER-2-neu, CEA Peptides, GM-CSF, Montanide ISA-51 Vaccine
Pharmacologic Substance
C1708269
C48392
Term relations
- Agent Combination Not Indexed in Open Clinical Trials
- Chemotherapy_Regimen_Has_Component some Recombinant Granulocyte-Macrophage Colony-Stimulating Factor
- Chemotherapy_Regimen_Has_Component some Incomplete Freund's Adjuvant
- Chemotherapy_Regimen_Has_Component some Carcinoembryonic Antigen Peptide
- Chemotherapy_Regimen_Has_Component some HER-2/neu Peptide Vaccine